2022

Earlier this year, Connecticut Governor Ned Lamont proposed to set a maximum price on prescription drugs, drawing criticism from…

Despite significant improvement in the treatment of HER2-positive metastatic breast cancer in recent years, breast cancer remains…

Policy and Medicine Compliance Update is our monthly compliance publication designed to help compliance professionals go in depth…

On February 11, 2022, the United States Food and Drug Administration (FDA) Office of Prescription Drug Promotion (OPDP) sent a…

We have written several times on the December 2020 letter issued by the United States Department of Health and Human Services…

In light of the Coronavirus (COVID-19) pandemic, the Centers for Medicare and Medicaid Services (CMS) has been implementing…

Earlier this year, a handful of pharmaceutical companies reached a multi-million-dollar settlement with Tribal Nations over opioid…

In January 2022, the Federal Trade Commission (FTC) and the Department of Justice (DOJ) Antitrust Division announced a joint…

When the United States Centers for Medicare and Medicaid Services (CMS) enacted its price transparency rule on January 1, 2021,…

Earlier this year, the Government Accountability Office (GAO) issued a report that puts the Department of Health and Human…